Table 1.
Baseline demographic data and patient characteristics
| Propofol regimen (n = 65) | Midazolam regimen (n = 70) | P | |
|---|---|---|---|
| Gender, male [n (%)] | 45 (69.2) | 50 (71.4) | 0.851 |
| Age, ≥70 years [n (%)] | 39 (60.0) | 38 (54.3) | 0.121 |
| HBs‐Ag, positive [n (%)] | 11 (16.9) | 10 (14.3) | 0.813 |
| HCV‐Ab, positive [n (%)] | 40 (61.5) | 47 (67.1) | 0.590 |
| ECOG‐PS 0 [n (%)] | 58 (89.2) | 64 (91.4) | 0.774 |
| Child–Pugh score [n (%)] | |||
| 5 | 48 (73.8) | 51 (72.9) | 0.795 |
| 6 | 14 (21.5) | 15 (21.4) | |
| 7 | 1 (1.5) | 3 (4.3) | |
| 8 | 2 (3.1) | 1 (1.4) | |
| Tumor number [n (%)] | |||
| 1 | 45 (69.2) | 49 (70.0) | 0.834 |
| 2 | 17 (26.2) | 16 (22.9) | |
| 3 | 3 (4.6) | 5 (7.1) | |
| Maximum tumor size in mm [mean (SD)] | 17.4 (5.9) | 16.4 (5.6) | 0.319 |
| Single nodule and ≤20 mm [n (%)] | 30 (46.2) | 34 (48.6) | 0.863 |
| AFP value, ng/mL [mean (SD)] | 51.8 (175.4) | 78.7 (332.1) | 0.553 |
| Tumor location, nearby vessels [n (%)] | 41 (63.1) | 44 (62.9) | 1.000 |
| Past history of RFA [n (%)] | 30 (46.2) | 35 (50.0) | 0.864 |
Abbreviations: AFP, alpha‐fetoprotein; ECOG‐PS, Eastern Cooperative Oncology Group performance status; HBs‐Ag, hepatitis B surface antigen; HCV‐Ab, hepatitis C virus antibody; RFA, radiofrequency ablation.